Key points are not available for this paper at this time.
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTPharmacological Options in the Treatment of Benign Prostatic HyperplasiaBarry Kenny, Stephen Ballard, Julian Blagg, and David FoxView Author Information Departments of Discovery Biology and Discovery Chemistry, Pfizer Central Research, Sandwich, Kent CT13 9NJ, U.K. Cite this: J. Med. Chem. 1997, 40, 9, 1293–1315Publication Date (Web):April 25, 1997Publication History Received7 October 1996Published online25 April 1997Published inissue 1 April 1997https://pubs.acs.org/doi/10.1021/jm960697shttps://doi.org/10.1021/jm960697sreview-articleACS PublicationsCopyright © 1997 American Chemical SocietyRequest reuse permissionsArticle Views977Altmetric-Citations147LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Anatomy,Antagonists,Inhibitors,Receptors,Selectivity Get e-Alerts
Kenny et al. (Tue,) studied this question.